Alectinib Granted FDA Approval as First-line Therapy for ALK-positive NSCLC

Share this content:
Approval was based on results from ALEX, in which patients with ALK-positive NSCLC not previously treated with systemic therapy were randomly assigned to receive alectinib or crizotinib.
Approval was based on results from ALEX, in which patients with ALK-positive NSCLC not previously treated with systemic therapy were randomly assigned to receive alectinib or crizotinib.

The US Food and Drug Administration (FDA) granted approval to alectinib as a first-line therapy for patients with ALK-positive metastatic non–small cell lung cancer (NSCLC), according to a press release.1

The FDA based its approval on results from the open-label phase 3 ALEX trial (ClinicalTrials.gov Identifier: NCT02075840), for which researchers randomly assigned 303 patients with ALK-positive NSCLC not previously treated with systemic therapy to receive alectinib or crizotinib.

Patients treated with alectinib had a significantly reduced risk of disease progression or death of 47% (hazard ratio [HR], 0.53; 95% CI, 0.38-0.73; P < .0001) compared with patients treated with crizotinib.

The median progression-free survival (PFS) was 25.7 months (95% CI, 19.9-not evaluable) vs 10.4 months (95% CI, 7.7-14.6) for patients in the alectinib vs crizotinib arm, respectively.

Patients treated with alectinib also had a lower risk of brain or central nervous system metastases compared with those treated with crizotinib (85%; HR, 0.16; 95% CI, 0.10-0.28; P < .0001).

Updated safety reports for alectinib remained consistent with those previously reported from prior studies. The most frequently reported grade 3 and 4 adverse reactions included kidney dysfunction, hyponatremia, impaired liver function, and anemia.

Reference

1. FDA approves Roche's Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer [news release]. Basel, Switzerland: Roche; November 7, 2017. https://www.roche.com/media/store/releases/med-cor-2017-11-07.htm?utm_source=360Works%20CloudMail&utm_medium=email&utm_campaign=12739. Accessed November 7, 2017.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs